William Blair Has Positive Forecast for NMRA Q3 Earnings

Key Points

• William Blair has revised its Q3 2025 earnings estimate for Neumora Therapeutics to ($0.28) per share, an improvement from the prior estimate of ($0.30).
• Neumora Therapeutics beat earnings expectations for their latest quarter, reporting ($0.33) EPS compared to the consensus estimate of ($0.38).
• The current consensus target price for Neumora Therapeutics stands at $7.14, with a mixed rating from analysts, including one sell, five holds, and three buy ratings.

Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) - William Blair upped their Q3 2025 earnings estimates for Neumora Therapeutics in a note issued to investors on Wednesday, August 6th. William Blair analyst M. Minter now anticipates that the company will post earnings of ($0.28) per share for the quarter, up from their prior forecast of ($0.30). The consensus estimate for Neumora Therapeutics' current full-year earnings is ($1.61) per share. William Blair also issued estimates for Neumora Therapeutics' Q4 2025 earnings at ($0.29) EPS, FY2025 earnings at ($1.32) EPS, Q1 2026 earnings at ($0.27) EPS, Q2 2026 earnings at ($0.20) EPS, Q3 2026 earnings at ($0.21) EPS, Q4 2026 earnings at ($0.22) EPS, FY2026 earnings at ($0.90) EPS, FY2027 earnings at ($0.91) EPS and FY2028 earnings at ($0.47) EPS.

Several other equities analysts have also weighed in on the stock. Needham & Company LLC restated a "buy" rating and issued a $5.00 price objective on shares of Neumora Therapeutics in a report on Tuesday, May 13th. Mizuho increased their price objective on shares of Neumora Therapeutics from $4.00 to $5.00 and gave the stock an "outperform" rating in a research report on Wednesday, July 16th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and three have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Neumora Therapeutics has an average rating of "Hold" and an average price target of $7.14.

Neumora Therapeutics Price Performance

Shares of NMRA stock traded down $0.04 during trading hours on Monday, reaching $1.53. 230,868 shares of the company were exchanged, compared to its average volume of 2,093,414. Neumora Therapeutics has a fifty-two week low of $0.61 and a fifty-two week high of $17.19. The stock's fifty day moving average is $1.28 and its two-hundred day moving average is $1.18. The company has a market cap of $246.97 million, a price-to-earnings ratio of -0.98 and a beta of 2.91. The company has a debt-to-equity ratio of 0.11, a current ratio of 10.54 and a quick ratio of 10.54.

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.33) EPS for the quarter, beating analysts' consensus estimates of ($0.38) by $0.05.

Institutional Trading of Neumora Therapeutics

A number of large investors have recently added to or reduced their stakes in NMRA. Capital International Investors lifted its stake in Neumora Therapeutics by 692.1% in the fourth quarter. Capital International Investors now owns 3,700,359 shares of the company's stock valued at $39,224,000 after acquiring an additional 3,233,179 shares during the last quarter. Lunate Capital Ltd acquired a new stake in Neumora Therapeutics in the first quarter valued at $2,124,000. Graham Capital Management L.P. lifted its stake in Neumora Therapeutics by 1,643.7% in the first quarter. Graham Capital Management L.P. now owns 1,162,499 shares of the company's stock valued at $1,162,000 after acquiring an additional 1,095,830 shares during the last quarter. AQR Capital Management LLC acquired a new stake in Neumora Therapeutics in the first quarter valued at $463,000. Finally, Stempoint Capital LP acquired a new stake in Neumora Therapeutics in the fourth quarter valued at $4,538,000. Institutional investors and hedge funds own 47.65% of the company's stock.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.